Company profile
Aditxt, Inc.
NASDAQ: ADTX · Healthcare · Biotechnology
PublicHQ Mountain View, VACIK 0001726711Reports USD
#1147 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
18DFH 15DQ 22GM 11SS 39
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$14.3k
Rev growth YoY (TTM)
-74.1%
Net income (FY)
-$43.1M
Employees
26
as of 2026-08-31
Market cap
$7.7M
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.2k$3.2k2025
Net income-$43.1M-$43.1M2025
Operating income-$19.6M-$19.6M2025
Total assets$16.5M$16.5M2025
Liabilities$12.6M$12.6M2025
Equity$5.6M$5.6M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aditxt, Inc.’s revenue?
Aditxt, Inc. booked $3.2k in FY2025 revenue, contracting 98% year over year — among the slowest-growing Healthcare companies we track, at a -1349028.2% net margin.
Peers · Healthcare
HeartSciences Inc.——Caring Brands, Inc.22DBiora Therapeutics, Inc.——Accelera Innovations, Inc——Instadose Pharma Corp.——Aibotics Inc.14DKey facts
CEOJeffrey Busch
SectorHealthcare
IndustryBiotechnology
HeadquartersMountain View, VA
ExchangeNASDAQ: ADTX
Employees26
IPO date2020-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.